Exosome atomizing agent for treating rhinitis and preparation method thereof

Abstract

The invention discloses an exosome atomizing agent for treating rhinitis. The exosome atomizing agent is prepared from the following raw materials: exosome, a solvent and curcumin, specifically, the exosome is 0.1-1 * 10 < 9 > / mL, the solvent volume capacity is 90-99%, and the curcumin is 1-20 mg / mL. The use of exosomes in the treatment of rhinitis may reduce side effects compared to conventional drugs because they are natural cell products and can target specific cell types; the exosome can carry various bioactive molecules such as protein, RNA and DNA, and the molecules can achieve a synergistic effect to enhance the treatment effect; the exosome can be used as a drug delivery system to effectively transfer the therapeutic molecule curcumin to target cells, so that the local drug concentration is improved.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an exosome atomizer for treating rhinitis and a preparation method thereof. Background Art

[0002] Rhinitis is a common respiratory disease with various causes, including the following: Infections by pathogens such as viruses, bacteria, and fungi are common causes of rhinitis, especially viral colds, which often cause acute rhinitis; rapid changes in temperature and humidity, cold air stimulation, etc. may induce or aggravate rhinitis; and bad habits such as smoking and drinking can irritate the nasal mucosa and cause rhinitis. In modern medicine, drugs are generally used for treatment, and nasal irrigation can be used in more severe cases to relieve the symptoms of rhinitis.

[0003] Common drug treatments are mostly Western medicines, which are usually easy to use and can target the specific cause of rhinitis, such as antibiotics for bacterial infections and antihistamines for allergic reactions. They can quickly relieve the acute symptoms of rhinitis. However, most Western medicines are antibiotics, which may cause some side effects when used, such as drowsiness and dry mouth. In addition, long-term use may lead to drug dependence, and symptoms may rebound after stopping the drug.

[0004] Traditional Chinese medicine has also developed many treatment prescriptions and methods, such as Guizhi Decoction and Mahuang Decoction for warming the lungs and cold, Buzhong Yiqi Decoction for invigorating qi, strengthening the spleen and raising yang, Yinqiao Powder for dispersing wind and dissipating heat, and various external powders, etc. It can also be effective in improving the physical condition of patients with rhinitis and alleviating the symptoms of rhinitis, but the use process of Chinese medicine prescriptions is somewhat cumbersome, especially the decoction, which requires patients to make it every day according to the treatment cycle, which is not conducive to patients carrying it out. For this reason, the present application proposes an exosome atomizer for treating rhinitis with exosomes as the main component. Summary of the invention

[0005] The embodiments of the present application provide an exosome aerosol for treating rhinitis and a preparation method thereof. Compared with traditional drugs, the use of exosomes for treating rhinitis may reduce side effects because they are natural cell products and can target specific cell types; exosomes can carry a variety of bioactive molecules, such as proteins, RNA, DNA, etc., which can work synergistically to enhance the therapeutic effect; exosomes can be used as a drug delivery system to effectively deliver the therapeutic molecule curcumin to target cells and increase local drug concentration.

[0006] The embodiment of the present application provides an exosome atomizer for treating rhinitis, comprising the following raw materials: exosomes, solvent, curcumin;

[0007] The specific exosomes are 0.1-1x10^9 / mL, the solvent volume capacity is 90-99%, and the curcumin is 1-20mg / mL.

[0008] Exosomes are tiny vesicles secreted by mesenchymal stem cells, which effectively relieve the symptoms of allergic rhinitis mainly through mechanisms such as immune regulation, inflammation inhibition, and tissue repair;

[0009] Exosomes are extracted from dental pulp mesenchymal stem cells. The specific process of extracting exosomes from dental pulp mesenchymal stem cells is as follows:

[0010] 2.1 Isolation and culture of dental pulp mesenchymal stem cells

[0011] Dental pulp tissue is extracted from the patient's extracted wisdom teeth or other teeth, treated with enzyme digestion (such as collagenase), and dental pulp mesenchymal stem cells are separated. The separated stem cells are cultured in a culture medium containing specific growth factors (such as fibroblast growth factor, platelet-derived growth factor, etc.) to promote their proliferation.

[0012] 2.2 Induction of dental pulp mesenchymal stem cells

[0013] Optimizing stem cell function by changing the composition of the culture medium or adding specific induction factors.

[0014] 2.3 Collection of exosomes

[0015] When the stem cells reach a certain density, fresh culture medium is replaced and the culture supernatant is collected after 24-48 hours. The supernatant is centrifuged at 300-2000g for 10-15 minutes to remove cells and cell debris. The supernatant is transferred to an ultracentrifuge tube and centrifuged at 100000g for 70-90 minutes to precipitate exosomes. The supernatant is discarded and the precipitate is washed with an appropriate amount of PBS or saline and ultracentrifuged again to wash the exosomes.

[0016] 2.4 Exosome purification

[0017] Exosomes were further purified using sucrose or iodixanol density gradient centrifugation.

[0018] The function of dental pulp mesenchymal stem cells was further optimized using the culture medium of DPSCs. The optimization process is as follows:

[0019] 2.2.1 Selection of basal culture medium

[0020] The basic culture medium is composed of DMEM / F-12, human serum (10-20%), penicillin and streptomycin, L-glutamine (2mM), sodium pyruvate (1mM), and HEPES (10-25mM) to provide basic nutrition and energy for cell growth;

[0021] 2.2.2 Dental pulp mesenchymal stem cell culture

[0022] Dental pulp mesenchymal stem cells were cultured and inoculated into a culture dish containing a basic culture medium, and cultured in an incubator at 37°C and 5% CO2, with fresh culture medium replaced regularly; bFGF (2-10 ng / mL) growth factor was added to the culture medium to promote cell proliferation.

[0023] The solvent is 0.9% NaCl solution, which has little irritation to the nasal mucosa.

[0024] Curcumin is a major active ingredient extracted from the rhizome of turmeric. It belongs to the class of polyphenolic compounds and has a variety of biological activities. Curcumin is a powerful anti-inflammatory agent that can inhibit some key molecules in the inflammatory process, such as NF-κB (nuclear factor-κB), COX-2 (cyclooxygenase-2), iNOS (inducible nitric oxide synthase) and a variety of inflammatory cytokines (such as tumor necrosis factor-α, interleukin-1β, interleukin-6, etc.). These molecules play an important role in the inflammatory process of rhinitis, so the anti-inflammatory properties of curcumin may help alleviate the symptoms of rhinitis.

[0025] The method for preparing an exosome aerosol for treating rhinitis using the above raw materials specifically includes the following steps:

[0026] (1.1) Solvent preparation: Prepare 0.9% saline solution and ensure sterility;

[0027] (1.2) Dissolving curcumin: Dissolve curcumin and then slowly add it into normal saline and stir evenly;

[0028] (1.3) Exosome mixing: The purified exosomes were slowly added to the saline solution containing dissolved curcumin, and gentle stirring or rotation mixing was used to ensure uniform distribution of the exosomes;

[0029] (1.4) Adjusting the pH value of the solution: Use phosphate buffered saline (PBS) to adjust the pH value of the mixture to close to physiological pH (about 7.4);

[0030] (1.5) Adjusting the pH value of the drug: adding buffers to the drug to adjust the pH value of the liquid; adding excipients such as glycerol, polyethylene glycol (PEG), hyaluronic acid, etc. to improve stability and spray performance;

[0031] (1.6) Performance testing: stability testing and biological activity testing are performed to ensure the quality of the aerosol;

[0032] (1.7) Sterilization operation: Use filtration sterilization or other appropriate methods to sterilize the aerosol;

[0033] (1.8) Filling and sealing: Fill the sterile medicine into the nebulizer bottle and then seal it for storage.

[0034] Curcumin needs to be dissolved separately in advance (a small portion of normal saline can be taken separately, and then a surfactant is used to fully dissolve the curcumin in the normal saline).

[0035] One or more technical solutions provided in the embodiments of the present application have at least the following technical effects or advantages:

[0036] 1. Compared with traditional drugs, the use of exosomes in the treatment of rhinitis may reduce side effects because they are natural cell products and can target specific cell types; exosomes can carry a variety of bioactive molecules, such as proteins, RNA, DNA, etc., which can work synergistically to enhance the therapeutic effect; exosomes can be used as a drug delivery system to effectively deliver the therapeutic molecule curcumin to target cells and increase local drug concentration.

[0037] 2. Exosomes and curcumin have a synergistic effect. Exosomes regulate immune responses and promote cell repair, while curcumin has anti-inflammatory and antioxidant properties. The combination of the two can more effectively treat rhinitis. Exosomes can selectively target specific cells or tissues, allowing curcumin to act more directly on the site of rhinitis. Curcumin also has a strong anti-inflammatory effect. When used in combination with exosomes, it can more effectively reduce the inflammatory response caused by rhinitis. DETAILED DESCRIPTION

[0038] In order to facilitate understanding of the present invention, the present invention is described more fully below. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention more thoroughly understood.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0040] Embodiment 1

[0041] An exosome atomizer for treating rhinitis, comprising the following raw materials: exosomes, solvent, and curcumin;

[0042] The specific exosomes are 0.1-1x10^9 / mL, the solvent volume capacity is 90-99%, and the curcumin is 1-20mg / mL.

[0043] Exosomes are extracted from dental pulp mesenchymal stem cells and effectively relieve the symptoms of allergic rhinitis mainly through mechanisms such as immune regulation, inflammation inhibition, and tissue repair.

[0044] Exosomes extracted from dental pulp mesenchymal stem cells are used to treat rhinitis, and their cell activity is verified by in vitro and in vivo experimental tests.

[0045] In vitro test:

[0046] Exosomes were extracted from dental pulp mesenchymal stem cells and purified using ultracentrifugation and other methods. The morphology of exosomes was then observed using transmission electron microscopy, the particle size and concentration of exosomes were determined by nanoparticle tracking analysis (NTA), and marker proteins of exosomes (such as TSG101, CD63, etc.) were identified using Western blot and other methods.

[0047] Cultivate rhinitis-related cell lines, such as nasal epithelial cells or inflammatory cells, co-culture exosomes with cells, set different concentrations and time gradients, and the control group can be untreated cells or cells with an equal volume of culture medium added;

[0048] CCK-8 or MTT kits were used to detect cell proliferation, and flow cytometry was used to analyze cell apoptosis and cell cycle.

[0049] In vivo experimental testing:

[0050] Select a suitable animal model (such as mice) and establish a rhinitis model. Administer the extracted exosomes to the animals by nasal instillation or systemic administration. Set up a control group and experimental groups with different doses.

[0051] At designated time points, nasal mucosal tissues were removed and subjected to HE staining or other special staining to assess the degree of tissue lesions and inflammation.

[0052] Curcumin can inhibit some key molecules in the inflammatory process, such as NF-κB (nuclear factor-κB), COX-2 (cyclooxygenase-2), iNOS (inducible nitric oxide synthase) and a variety of inflammatory cytokines (such as tumor necrosis factor-α, interleukin-1β, interleukin-6, etc.). These molecules play an important role in the inflammatory process of rhinitis, so the anti-inflammatory properties of curcumin may help alleviate the symptoms of rhinitis;

[0053] Curcumin is extracted from turmeric rhizomes. To ensure the efficient extraction efficiency of curcumin, the following process is used to extract curcumin:

[0054] (3.1) Wash the turmeric rhizome, dry it, and then grind it into 50-60 mesh powder;

[0055] (3.2) Select an organic solvent, such as anhydrous ethanol, weigh a certain amount of turmeric powder, and stir and mix the turmeric powder and the organic solvent in a solid-liquid ratio of 1:10 (1 gram of turmeric powder plus 10 ml of organic solvent).

[0056] (3.3) The mixed solution is placed in an ultrasonic extractor and extracted at a frequency of 25-35 kHz and a temperature of 45-65°C for 30-45 minutes;

[0057] (3.4) After extraction, the solution is passed through filter paper or centrifuged to remove solid impurities, and then the filtrate is concentrated by an evaporator to remove most of the solvent to obtain a curcumin concentrate;

[0058] (3.5) The curcumin solution is freeze-dried or vacuum-dried to obtain curcumin solid, which is then ground into powder using a ball mill and finally sealed and packaged.

[0059] Since curcumin is a highly hydrophobic compound with poor solubility in water, in order to ensure that the curcumin powder can be fully dissolved in saline, follow the following process:

[0060] (4.1) Add an appropriate amount of non-ionic surfactant (such as polysorbate (Tween) or poloxamer (Pluronic)) to normal saline and stir evenly. Slowly add curcumin powder to the pre-mixed normal saline while stirring continuously;

[0061] (4.2) An ultrasonic bath is used to further help the curcumin dissolve. If there is undissolved curcumin or impurities in the solution, they can be removed by filtration.

[0062] The preparation of an exosome nebulizer for treating rhinitis using the above raw materials includes the following processes: preparing a 0.9% saline solution, fully dissolving curcumin in advance and then slowly adding it to the saline solution and stirring evenly; slowly adding the purified exosomes to the saline solution containing dissolved curcumin, using gentle stirring or rotation mixing to ensure that the exosomes are evenly distributed; using phosphate buffered saline (PBS) to adjust the pH value of the mixture to close to the physiological pH (about 7.4); adding a buffer to the agent to adjust the pH value of the liquid; adding glycerol, polyethylene glycol (PEG), hyaluronic acid and other excipients to improve stability and nebulization performance; conducting stability tests and bioactivity tests to ensure the quality of the nebulizer; using filtration sterilization or other suitable methods to sterilize the nebulizer; filling the sterile agent into a nebulizer bottle, and then sealing it for storage.

[0063] The technical solutions in the above-mentioned embodiments of the present application have at least the following technical effects or advantages: compared with traditional drugs, the use of exosomes for the treatment of rhinitis may reduce side effects because they are natural cell products and can target specific cell types; exosomes can carry a variety of bioactive molecules, such as proteins, RNA, DNA, etc., which can work synergistically to enhance the therapeutic effect; exosomes can be used as a drug delivery system to effectively deliver the therapeutic molecule curcumin to target cells and increase local drug concentration.

[0064] Embodiment 2

[0065] An exosome atomizer for treating rhinitis, comprising the following raw materials: exosomes, solvent, and curcumin;

[0066] The specific exosomes are 0.1x10^9 / mL, the solvent volume capacity is 95%, and the curcumin is 7mg / mL.

[0067] The preparation of an exosome nebulizer for treating rhinitis using the above raw materials includes the following processes: preparing a 0.9% saline solution, fully dissolving curcumin in advance and then slowly adding it to the saline solution and stirring evenly; slowly adding the purified exosomes to the saline solution containing dissolved curcumin, using gentle stirring or rotation mixing to ensure that the exosomes are evenly distributed; using phosphate buffered saline (PBS) to adjust the pH value of the mixture to close to the physiological pH (about 7.4); adding a buffer to the agent to adjust the pH value of the liquid; adding glycerol, polyethylene glycol (PEG), hyaluronic acid and other excipients to improve stability and nebulization performance; conducting stability tests and bioactivity tests to ensure the quality of the nebulizer; using filtration sterilization or other suitable methods to sterilize the nebulizer; filling the sterile agent into a nebulizer bottle, and then sealing it for storage.

[0068] Embodiment 3

[0069] An exosome atomizer for treating rhinitis, comprising the following raw materials: exosomes, solvent, and curcumin;

[0070] The specific content is 0.7x10^9 exosomes / mL, the solvent volume capacity is 80%, and the curcumin is 11 mg / mL.

[0071] The preparation of an exosome nebulizer for treating rhinitis using the above raw materials includes the following processes: preparing a 0.9% saline solution, fully dissolving curcumin in advance and then slowly adding it to the saline solution and stirring evenly; slowly adding the purified exosomes to the saline solution containing dissolved curcumin, using gentle stirring or rotation mixing to ensure that the exosomes are evenly distributed; using phosphate buffered saline (PBS) to adjust the pH value of the mixture to close to the physiological pH (about 7.4); adding a buffer to the agent to adjust the pH value of the liquid; adding glycerol, polyethylene glycol (PEG), hyaluronic acid and other excipients to improve stability and nebulization performance; conducting stability tests and bioactivity tests to ensure the quality of the nebulizer; using filtration sterilization or other suitable methods to sterilize the nebulizer; filling the sterile agent into a nebulizer bottle, and then sealing it for storage.

[0072] Embodiment 4

[0073] An exosome atomizer for treating rhinitis, comprising the following raw materials: exosomes, solvent, and curcumin;

[0074] Specific exosomes: 1x10^9 / mL, solvent volume capacity: 99%, and curcumin: 17mg / mL.

[0075] The preparation of an exosome nebulizer for treating rhinitis using the above raw materials includes the following processes: preparing a 0.9% saline solution, fully dissolving curcumin in advance and then slowly adding it to the saline solution and stirring evenly; slowly adding the purified exosomes to the saline solution containing dissolved curcumin, using gentle stirring or rotation mixing to ensure that the exosomes are evenly distributed; using phosphate buffered saline (PBS) to adjust the pH value of the mixture to close to the physiological pH (about 7.4); adding a buffer to the agent to adjust the pH value of the liquid; adding glycerol, polyethylene glycol (PEG), hyaluronic acid and other excipients to improve stability and nebulization performance; conducting stability tests and bioactivity tests to ensure the quality of the nebulizer; using filtration sterilization or other suitable methods to sterilize the nebulizer; filling the sterile agent into a nebulizer bottle, and then sealing it for storage.

[0076] Application Examples

[0077] The aerosols prepared in Example 2, Example 3 and Example 4 were numbered in the order of 1, 2, and 3, and then 21 patients with rhinitis were selected, with seven people forming a group. All patients in the first group used aerosol No. 1, all patients in the second group used aerosol No. 2, and all patients in the third group used aerosol No. 3. The feedback from patients in each group after the treatment of rhinitis is shown in the following table:

[0078] Table 1 shows the feedback information of the first group on the treatment of rhinitis;

[0079]

[0080] According to the patient's rhinitis symptoms, it can be clearly seen that Nebulizer No. 1 can effectively alleviate the symptoms of rhinitis, but its therapeutic effect is somewhat weak for patients with more severe rhinitis symptoms.

[0081] Table 2 shows the feedback information of the second group on the treatment of rhinitis;

[0082]

[0083]

[0084] According to the patient's rhinitis symptoms, it can be clearly seen that Nebulizer No. 2 can effectively alleviate the symptoms of rhinitis, and its therapeutic effect is significant for patients with more severe rhinitis symptoms.

[0085] Table 3 shows the feedback information of the third group on the treatment of rhinitis;

[0086]

[0087] According to the patient's rhinitis symptoms, it can be clearly seen that nebulizer No. 3 can effectively alleviate the symptoms of rhinitis.

[0088] Experimental example

[0089] According to the raw materials, exosomes, solvent, curcumin; specifically, 0.1-1x10^9 exosomes / mL, 90-99% solvent volume capacity, and 1-20 mg / mL curcumin, the stability and bioactivity performance tests of the prepared atomizer for treating rhinitis are as follows:

[0090] Stability test

[0091] Dispense the prepared aerosol into several sterile vials;

[0092] The samples were stored under different conditions, such as room temperature, 4°C, -20°C, and light conditions at room temperature and 37°C;

[0093] Sampling at predetermined time points (e.g., 0 day, 1 week, 1 month, 3 months, 6 months);

[0094] Test the pH value, appearance, active ingredient concentration, microbial contamination, etc. of the samples.

[0095] The data results are shown in Table 4:

[0096]

[0097] Table 4

[0098] The nebulizer is relatively stable within 90 days when stored under refrigerated and frozen conditions, but the concentration of active ingredients decreases slightly when stored at room temperature for 180 days. It is recommended to store it under refrigerated conditions.

[0099] Biological activity test

[0100] Use nasal mucosal epithelial cells for culture;

[0101] The aerosol is diluted in a certain ratio and applied to the cells, and a control group and experimental groups with different concentrations are set up;

[0102] The cell activity and anti-inflammatory effect were detected by MTT and cytokine assays.

[0103] The data results are shown in Table 5:

[0104]

[0105] Table 5

[0106] The nebulizer significantly increased cell activity and reduced the level of inflammatory factor TNF-α at low and medium doses, while increasing the level of anti-inflammatory factor IL-10, indicating that it has anti-inflammatory effects. Cell activity decreased slightly at high doses.

[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An exosome aerosol for treating rhinitis, characterized in that: The following raw materials are included: exosomes, solvent, curcumin; Specific exosomes 0.1-1x10^9 / mL, solvent volume capacity 90-99%, curcumin 1-20mg / mL; The method for preparing an exosome aerosol for treating rhinitis using the above raw materials specifically includes the following steps: (1.1) Solvent preparation: Prepare 0.9% saline solution and ensure sterility; (1.2) Dissolving curcumin: Dissolve curcumin and then slowly add it into normal saline and stir evenly; (1.3) Exosome mixing: The purified exosomes were slowly added to the saline solution containing dissolved curcumin, and gentle stirring or rotation mixing was used to ensure uniform distribution of the exosomes; (1.4) Adjust the pH value of the solution: Use phosphate buffer to adjust the pH value of the mixture; (1.5) Adjusting the pH value of the agent: adding buffers to the agent to adjust the pH value of the liquid; adding glycerol, polyethylene glycol, and hyaluronic acid excipients to improve stability and spray performance; (1.6) Performance testing: stability testing and biological activity testing are performed to ensure the quality of the aerosol; (1.7) Sterilization operation: Use filtration sterilization or other appropriate methods to sterilize the aerosol; (1.8) Filling and sealing: Fill the sterile medicine into the nebulizer bottle and then seal it for storage.

2. The exosome aerosol for treating rhinitis according to claim 1, characterized in that: Exosomes are extracted from dental pulp mesenchymal stem cells. The specific process of extracting exosomes from dental pulp mesenchymal stem cells is as follows: 2.1 Isolation and culture of dental pulp mesenchymal stem cells Extract dental pulp tissue from wisdom teeth or other teeth extracted from patients, treat the dental pulp tissue using enzyme digestion, separate dental pulp mesenchymal stem cells, and culture the separated stem cells in a culture medium containing specific growth factors to promote their proliferation; 2.2 Induction of dental pulp mesenchymal stem cells Optimizing stem cell function by changing the composition of the culture medium or adding specific induction factors; 2.3 Collection of exosomes When the stem cells reach a certain density, replace the culture medium with fresh one, collect the culture supernatant after 24-48 hours, centrifuge the supernatant at 300-2000g for 10-15 minutes to remove cells and cell debris, transfer the supernatant to an ultracentrifuge tube, and centrifuge it at 100000g for 70-90 minutes to precipitate the exosomes, discard the supernatant, wash the precipitate with an appropriate amount of PBS or saline, and ultracentrifuge it again to wash the exosomes; 2.4 Exosome purification Exosomes were further purified using sucrose or iodixanol density gradient centrifugation.

3. The exosome aerosol for treating rhinitis according to claim 2, characterized in that: To further optimize the function of dental pulp mesenchymal stem cells, the optimization process is as follows: 2.2.1 Selection of basal culture medium DMEM / F-12, human serum, penicillin and streptomycin, L-glutamine, sodium pyruvate, and HEPES were used to form the basal culture medium to provide basic nutrition and energy for cell growth; 2.2.2 Dental pulp mesenchymal stem cell culture Dental pulp mesenchymal stem cells were cultured and inoculated into a culture dish containing a basic culture medium, and cultured in an incubator at 37° C. and 5% CO 2 , with fresh culture medium replaced regularly; bFGF growth factor was added to the culture medium to promote cell proliferation.

4. The exosome aerosol for treating rhinitis according to claim 1, characterized in that: Curcumin is extracted from turmeric rhizomes. To ensure the efficient extraction efficiency of curcumin, the following process is used to extract curcumin: (3.1) Wash the turmeric rhizome, dry it, and then grind it into 50-60 mesh powder; (3.2) Select an organic solvent, such as anhydrous ethanol, weigh a certain amount of turmeric powder, and stir and mix the turmeric powder and the organic solvent in a solid-liquid ratio of 1:10; (3.3) The mixed solution is placed in an ultrasonic extractor and extracted at a frequency of 25-35 kHz and a temperature of 45-65°C for 30-45 minutes; (3.4) After extraction, the solution is passed through filter paper or centrifuged to remove solid impurities, and then the filtrate is concentrated by an evaporator to remove most of the solvent to obtain a curcumin concentrate; (3.5) The curcumin solution is freeze-dried or vacuum-dried to obtain curcumin solid, which is then ground into powder using a ball mill and finally sealed and packaged.

5. The exosome aerosol for treating rhinitis according to claim 4, characterized in that: To ensure that the curcumin powder can be fully dissolved in saline, follow the following process: (4.1) Add an appropriate amount of nonionic surfactant to normal saline and stir evenly. Slowly add curcumin powder to the pre-mixed normal saline while stirring continuously; (4.2) An ultrasonic bath is used to further help the curcumin dissolve. If there is undissolved curcumin or impurities in the solution, they can be removed by filtration.

6. The exosome aerosol for treating rhinitis according to claim 5, characterized in that: The nonionic surfactant may be any one of polysorbate or poloxamer.

Images